IL-36 Receptor Antagonist Spesolimab for Generalized Pustular Psoriasis Combined with Palmoplantar Pustulosis: A Case Report.

OBJECTIVE

We have entered the era of using biologics and small-molecule targeted drugs to treat diseases. Although there have been many reports on the use of the anti-interleukin-36 (IL-36) receptor antagonist spesolimab for the treatment of generalized pustular psoriasis (GPP) recently, the clinical application of spesolimab for the treatment of GPP combined with PPP (palmoplantar pustulosis) is rarely reported, and there is a lack of evidence on the safety and efficacy of the spesolimab.The clinical application of spesolimab for GPP combined with palmoplantar pustulosis (PPP) is rarely reported, and evidence on its safety and efficacy remains insufficient. We aimed to explore the use of spesolimab for GPP combined with PPP and observed significant efficacy without obvious side effects, thereby providing new ideas for the clinical treatment of GPP combined with PPP.

METHODS

We reported a case of GPP combined with PPP treated with spesolimab, which achieved significant therapeutic effects without significant side effects.

RESULTS

This case report shows that spesolimab has good clinical efficacy in treating GPP combined with PPP. In this case, the presence of PPP may have delayed the rapid and complete clearance of the skin lesions.

CONCLUSION

Spesolimab provides a new treatment option for patients with GPP combined with PPP.